Fig. 6

Downregulation of FGF19 reduced cell viability in A2780-CP20 cells. (A) Pharmacogenomic analysis of FGF18 and FGF19 was performed in the AZD4547-resistant group compared with the AZD4547-sensitive group (*p < 0.05). (B) The level of secreted FGF19 in EOC cell lines was assessed by ELISA. (C) A2780-CP20 cells were transfected with FGF19-siRNA (50 nM) or control siRNA and incubated for 72 h. Transfected cells were then exposed to 1 µM AZD4547 for 24 or 48 h, and cell viability was assessed by MTT assay (*p < 0.05, **p < 0.001). (D) Combination effect of AZD4547 with FGF401, an FGFR4 inhibitor, was assessed in A2780 and A2780-CP20 cells by MTT assay at 48 h. (E) A schematic representation of targeted therapy of FGF/FGFR in chemo-sensitive and chemo-resistant EOCs